secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuo Therapeutics, Inc. (AURX)
CIK:        0001091596
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001437749-25-017214
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products
--------------------------------------------------------------------------------

- Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.
- Smith+Nephew receives commission on net sales of Nuo branded products sold to its customers under interim arrangement.
- Interim agency terminates by Dec 31, 2025 or earlier with 30 days written notice.
- Underlying five-year Distribution Agreement for Nuo to supply private-label Aurix to Smith+Nephew remains in effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/0001437749-25-017214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/aurx20250514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-017214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer